Results 181 to 190 of about 419,158 (294)

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL. [PDF]

ESMO Real World Data Digit Oncol
Stickeler E, Decker T, Zahn MO, Thill M, Zaiss M, Nusch A, Teutsch C, Wang M, Kuske A, Ringwald K, Kruggel L, Harbeck N, Wöckel A, Welt A, Gratzke K, OPAL registry group.   +15 more
europepmc   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Correction: Boikos et al. Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review. <i>Vaccines</i> 2025, <i>13</i>, 381. [PDF]

Vaccines (Basel)
Boikos C, Schaible K, Nunez-Gonzalez S, Welch V, Hu T, Kyaw MH, Choi LE, Kamar J, Goebe H, McLaughlin J.   +9 more
europepmc   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

1,1‐Disubstituted Vinylbromides: Versatile Building Blocks for the Synthesis of Nitrogen‐Containing Heterocycles

European Journal of Organic Chemistry, EarlyView.
1,1‐Disubstituted vinylbromides are key intermediates for constructing nitrogen‐containing heterocycles. This review provides an overview of the synthetic applications of 1,1‐disubstituted vinylbromides and summarizes recent developments in reaction methodologies, mechanistic insights, and the structural diversity of N‐heterocyclic compounds accessible
Anne Westermeyer, Jun Fang, Chonghuo Liu, Guillaume Lefèvre, Gérard Guillamot, Phannarath Phansavath, Virginie Ratovelomanana‐Vidal   +6 more
wiley   +1 more source

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus. [PDF]

Breast
De Angelis C, de Biase D, Gerratana L, Arpino G, Bianchini G, Castellano I, Curigliano G, Del Mastro L, Fabi A, Fusco N, Gennari A, Guarneri V, Zamagni C, Zambelli A, Malapelle U, Puglisi F.   +15 more
europepmc   +1 more source

SV2A expression in blood cells as a possible biomarker candidate for levetiracetam treatment response

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to evaluate whether synaptic vesicle protein 2A (SV2A) expression on peripheral immune cells predicts treatment response to levetiracetam in epilepsy. Methods High‐dimensional flow cytometry was used to prospectively assess SV2A expression on immune cells from levetiracetam responders, nonresponders, and ...
Johannes Lang, Mathias Linnerbauer, Jeanne Cuny, Veit Rothhammer, Hajo Hamer   +4 more
wiley   +1 more source

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. [PDF]

J Clin Oncol
Hurvitz SA, Layman RM, Curigliano G, André F, Cristofanilli M, Kim SB, Martínez Rodríguez JL, Nadal JC, Kim GM, Lo L, Remolina-Bonilla YA, Rosselli G, Emile G, Korbenfeld E, Puig JM, Wesolowski R, Martin M, Ring A, Han HS, Giordano A, Mutka SC, Moss K, Suzuki S, Sullivan B, Gorbatchevsky I, Pistilli B, VIKTORIA-1 Study Group.   +26 more
europepmc   +1 more source

Defining the end point of status epilepticus: A scoping review and framework for standardization

Epilepsia, EarlyView.
Abstract Status epilepticus (SE) is a life‐threatening neurological emergency with consensus‐driven definitions for onset but no standardized criteria for its end point. This gap creates uncertainty in research and clinical practice. We conducted a scoping review to evaluate how end points have been defined in SE research and to identify key areas of ...
Fawad A. Khan, Margaret T. Gopaul, Samuel L. Carter, Anil Chimakurthy, Summer Skelton, Lawrence J. Hirsch, Eugen Trinka   +6 more
wiley   +1 more source